Showing results (11-20 of 117) with videos related to

Sort By:
Pageof 12
The Journal of Urology|January 10, 2004
Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated casesPeter Langenstroer, H J Porter, David G McLeod, et al.
Reviews in Urology|October 6, 2006
The emergence of radioimmunoscintigraphy for prostate cancerThomas E Keane, Inger L Rosner, M Scott Wingo, et al.
Urology|November 14, 2002
Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancerJohn A Taylor, Kevin J Gancarczyk, Gregory V Fant, et al.
BJU International|August 24, 2006
The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomyJohn A Taylor, Stacey G Koff, Deborah A Dauser, et al.
Cancer|September 22, 2007
Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancerRinaa S Punglia, Jennifer Cullen, David G McLeod, et al.
Cancer|February 23, 2007
Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortalityAnthony V D'Amico, David G McLeod, Peter R Carroll, et al.
Urologic Oncology|May 22, 2012
Health-related quality of life for men with prostate cancer--an evaluation of outcomes 12-24 months after treatmentStephen A Brassell, Sally I Elsamanoudi, Jennifer Cullen, et al.
Urology|November 8, 2011
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approachesRobert Dreicer, Dean F Bajorin, David G McLeod, et al.
Cancer|March 7, 2006
Lymphovascular invasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomyJoseph P Brooks, Paul S Albert, John O'Connell, et al.
BJU International|December 2, 2011
Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 yearsPeter Iversen, David G McLeod, William A See, et al.
Pageof 12